Results 1 to 10 of about 17,592 (206)

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Frontiers in Pharmacology, 2022
Palbociclib was approved by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal ...
Zhuo-Xun Wu, Zi-Ning Lei, Qiu-Xu Teng
exaly   +3 more sources

Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation

Current Oncology, 2022
Lung squamous cell carcinoma (LUSC) treatment response is poor and treatment alternatives are limited. Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, has recently been approved for hormone receptor-positive breast cancer patients and applied
Wenjing Xiang, Wanchen Qi, Huayu Li, Jia Sun, Chao Dong, Haojie Ou, Bing Liu   +6 more
doaj   +2 more sources

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

Pharmaceutics, 2022
Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia.
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, Marie Alexandre, Séverine Guiu, Nelly Firmin, Stéphane Pouderoux, Marie Viala, Gerald Lossaint, Chloé Gautier, Caroline Mollevi, Matthieu Gracia, Celine Gongora, Litaty Mbatchi, Alexandre Evrard, William Jacot   +15 more
doaj   +2 more sources

Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma

Journal of the Formosan Medical Association, 2021
Background/purpose: Palbociclib is an FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor that has been clinically proven to be effective in breast cancer. However, its use in oral cancer is not well researched.
Tong-Hong Wang, Chin-Chuan Chen, Yann-Lii Leu, Yun-Shien Lee, Jang-Hau Lian, Hsi-Lung Hsieh, Chi-Yuan Chen   +6 more
doaj   +1 more source

Lenvatinib and Palbociclib [PDF]

Hospital Pharmacy, 2015
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A, Solimando, J Aubrey, Waddell
openaire   +2 more sources

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer

Cell Death Discovery, 2023
Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii ...
Xianzhe Wang, Wei Shi, Xumei Wang, Jin-Jian Lu, Ping He, Hongjie Zhang, Xiuping Chen   +6 more
doaj   +1 more source

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan

Breast, 2023
Purpose: The optimal treatment following endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has not been established. We aimed to investigate treatment patterns and time to treatment failure (TTF) of subsequent therapy after ...
Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Hiroji Iwata   +3 more
doaj   +1 more source

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

Cancer Biology & Therapy, 2023
Background Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the ...
Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O’Neill, Bryan T. Hennessy, Sinead Toomey   +10 more
doaj   +1 more source

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Journal of Global Oncology, 2019
PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC)
John Waller, Debanjali Mitra, Katie Mycock, Gavin Taylor-Stokes, Gary Milligan, Lin Zhan, Shrividya Iyer   +6 more
doaj   +1 more source

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study

Cancer Treatment and Research Communications, 2022
Background: The incidence of breast cancer is rising in Japan, particularly in postmenopausal women. The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in patients with hormone receptor-positive (HR+), human epidermal growth ...
Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra   +6 more
doaj   +1 more source